201 results
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
regulations.
We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants … continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders
8-K
EX-99.1
0n4uth
24 Jan 24
Regulation FD Disclosure
8:50am
424B5
4e494wsc2ifm97s56
22 Dec 23
Prospectus supplement for primary offering
5:00pm
8-K
EX-4.2
o2myyt8pn
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-10.1
5og13 xbi9wz
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-4.1
yp3fz9tc gbpq
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-10.2
cdbtx8j
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
zsxvbwir
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
zqrh v4f6
13 Nov 23
Moleculin Reports Third Quarter 2023 Financial Results
8:00am
8-K
85qvzfxk1
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-99.1
f9ew832qd74tgy
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-99.1
2fij6ve8
10 Aug 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:05pm